FDA Approves Illumina Cancer Biomarker Test With Two Companion Diagnostics To Rapidly Match Patients To Targeted Therapies
Portfolio Pulse from Benzinga Newsdesk
Illumina's TruSight Oncology Comprehensive test receives FDA approval, marking it as the first US FDA-approved genomic profiling IVD kit with pan-cancer companion diagnostic claims. This test can identify biomarkers for targeted cancer therapies, benefiting patients with specific gene fusions.
August 27, 2024 | 1:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Illumina's TruSight Oncology Comprehensive test has been approved by the FDA, enhancing its product offerings in precision oncology. This approval could boost Illumina's market position and revenue potential in the genomic profiling market.
The FDA approval of Illumina's test is a significant milestone, likely to enhance its market position in precision oncology. The test's ability to profile over 500 genes and its companion diagnostic claims make it a valuable tool for targeted cancer therapies, potentially increasing demand and revenue for Illumina.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100